4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
Continuous vs. Fixed, 3 vs 2, PFS is the primary …
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
June 4, 202218m 1sExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/
Topics
medicineoncologyhealthpolicy